Aurobindo acquisitions aimed at making it big biosimilars player

Indian drugmaker Aurobindo Pharma (BSE: 524804) has bought four biosimilar products from Swiss firm TL Biopharmaceutical.

The deal, financial details of which have not been disclosed, will see TL supply all the developmental data for the four molecules, while Aurobindo will develop, commercialize and market the products globally.

Of the four biosimilars, three are monoclonal antibodies in oncology, including the lead molecule from the transaction, which is a version of Avastin (bevacizumab), a blockbuster drug sold by Swiss pharma major Roche (ROG: SIX).